9 METERS BIOPHARMA, INC. INNT Cash Flow

9 meters biopharma, inc. (INNT)

CashFlow / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16
Cash flows from operating activities
Net loss
-26,217	-27,048	-22,355	-13,909	-13,637	-24,162	-22,327	-24,002	-22,577	-11,605	-10,487	-9,870	-8,319	-6,213	0	0	0
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation
2,621	2,871	2,224	-1,807	-2,843	3,805	5,127	9,535	10,805	6,018	4,772	4,259	3,259	966	0	0	0
Accrued interest on convertible notes
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-
Accrued interest on convertible notes
-	-	-	-	-	-	319	271	361	396	0	0	0	-	-	-	-
Amortization of debt discount
1,473	1,067	1,167	1,723	2,160	2,513	2,070	1,191	456	39	0	0	0	-	-	-	-
Depreciation
21	21	21	20	22	19	17	13	7	5	0	0	0	-	-	-	-
Beneficial conversion feature
-	-	-	-	-	3,077	3,077	3,077	3,077	0	0	0	0	-	-	-	-
Change in fair value of derivative liability
-1,110	-873	-561	-332	-151	-50	0	0	0	-	-	-	-	-	-	-	-
Change in fair value of warrant liability
-667	54	-141	-2,669	-857	0	0	0	0	-	-	-	-	-	-	-	-
Warrant inducement expense
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-
Extinguishment of derivative liability
0	370	370	370	370	0	0	0	0	-	-	-	-	-	-	-	-
Amortization of deferred debt issuance costs and debt discount
-	-	-	-	-	-	-	-	-	-	-	-	-	740	0	0	0
Amortization of trademark
-	-	-	-	-	-	-	-	-	-	-	-	-	131	0	0	0
Gain on settlement of customer refund
-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0
Loss on extinguishment of debt
0	-1,049	-1,000	-1,000	-1,049	0	0	0	0	-	-	-	-	-	-	-	-
Provision for doubtful accounts
-	-	-	-	-	-	-	-	-	-	-	-	-	153	0	0	0
Changes in operating assets and liabilities:
Prepaid expenses and other assets
-314	50	211	821	507	298	478	215	193	155	0	0	0	-	-	-	-
Accounts receivable
-	-	-	-	-	-	-	-	-	-	-	-	-	365	0	0	0
Inventories
-	-	-	-	-	-	-	-	-	-	-	-	-	472	0	0	0
Prepaid expenses and other
-	-	-	-	-	-	-	-	-	-	-	-	-	478	0	0	0
Accounts payable
1,146	124	132	-682	1,862	86	-1,074	-107	-880	746	947	-633	-1,273	-753	0	0	0
Accrued expenses
3,950	3,921	1,474	727	644	-441	-1,424	-2,087	-2,299	-543	-1,441	-1,361	-557	-1,569	0	0	0
Accrued interest
0	-101	-101	-101	-101	0	0	0	0	-	-	-	-	-	-	-	-
Customer refund
-	-	-	-	-	-	-	-	-	-	-	-	-	-10	0	0	0
Due to related party
-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0
Net cash used in operating activities
-16,362	-17,967	-17,152	-16,644	-12,439	-15,169	-14,691	-12,323	-11,242	-5,096	0	0	0	-	-	-	-
Cash flows from investing activities
Purchase of property and equipment
-	-	-	-	-	13	51	51	51	38	0	0	0	-	-	-	-
Loan payments from related party
-	-	-	-	-	75	75	75	75	0	0	0	0	-	-	-	-
Net cash provided by investing activities
-11	-11	-84	-84	-75	-13	23	23	23	-38	0	0	0	-	-	-	-
Cash flows from financing activities
Borrowings from convertible notes
2,500	5,000	5,000	5,000	5,000	3,345	3,345	3,345	3,345	0	0	0	0	-	-	-	-
Repayments of Debt
0	-	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-
Proceeds from issuance of bridge financing
-	-	-	-	-	-	-	-	-	-	-	-	-	406	0	0	0
Proceeds from credit facility
-	-	-	-	-	-	-	-	-	-	-	-	-	641	0	0	0
Payments on credit facility
-	-	-	-	-	-	-	-	-	-	-	-	-	845	0	0	0
Payments of debt issuance costs
23	57	87	87	87	50	20	20	20	0	0	0	-75	57	0	0	0
Borrowings from convertible promissory notes
-	-	-	-	-	-	-	-	-	5,130	0	0	0	-	-	-	-
Payments of convertible notes
-	-	-	-	-	-	-	-	-	0	0	0	0	-	-	-	-
Net cash used in operating activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Proceeds from issuance of preferred stock, net
-	-	-	-	-	-	-	-	-	-	-	-	-	2,393	0	0	0
Proceeds from issuance of common stock and warrants
9,231	20,706	20,706	20,706	11,475	18,132	18,132	18,132	18,132	0	673	673	673	673	0	0	0
Payment of deferred offering costs
-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-
Payment of deferred offering costs
1,176	1,045	1,097	1,097	220	1,706	1,655	1,655	1,655	0	0	0	0	-	-	-	-
Payment of stock subscription receivable
-	-	-	-	-	-	-	-	-	0	0	0	0	-	-	-	-
Net cash provided by financing activities
7,547	16,843	17,989	19,403	11,032	20,556	21,300	22,957	24,082	5,130	0	0	0	-	-	-	-
Net (decrease) increase in cash and cash equivalents
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-
Net increase in cash and cash equivalents
-	-	-	-	-	-	-	10,658	12,864	-5	0	0	0	-	-	-	-
Net cash provided by financing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Net increase (decrease) in cash
-	-	-	-	-	-	-	-	-	-	-	-	-	1,334	0	0	0
Supplemental disclosure of cash flow information
Cash paid during the period for interest
509	874	418	418	568	280	280	280	130	0	4	30	44	59	0	0	0
Supplemental disclosure of non-cash financing activities
Conversion of convertible notes and accrued interest to common stock
-	-	-	-	-	9,229	9,229	9,229	9,229	0	0	0	0	-	-	-	-
Assumption of liabilities from reverse recapitalization transaction
-	-	-	-	-	978	978	978	978	0	0	0	0	-	-	-	-
Warrants issued to placement agents
-	-	-	-	-	913	913	913	913	0	0	0	0	-	-	-	-
Non-cash addition of derivative liability
370	1,281	1,701	1,701	1,701	420	0	0	0	-	-	-	-	-	-	-	-
Non-cash addition of deferred offering costs
0	151	205	205	205	54	0	0	0	-	-	-	-	-	-	-	-
Non-cash addition of derivative liability
370	1,281	1,701	1,701	1,701	420	0	0	0	-	-	-	-	-	-	-	-
Non-cash addition of deferred offering costs
0	151	205	205	205	54	0	0	0	-	-	-	-	-	-	-	-
Exchange of debt for equity
-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0